

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): October 21, 2020**

**Trevi Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-38886**  
(Commission  
File Number)

**45-0834299**  
(IRS Employer  
Identification No.)

**195 Church Street, 14th Floor**  
**New Haven, Connecticut**  
(Address of Principal Executive Offices)

**06510**  
(Zip Code)

**Registrant's telephone number, including area code: (203) 304-2499**

**Not applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
<b>Common stock, \$0.001 par value per share</b>	<b>TRVI</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other Events.**

On October 21, 2020, Trevi Therapeutics, Inc. (the “Company”) announced that patient screening had resumed in its Phase 2 clinical trial of Haduvio™ (nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis. The Company also announced that with the randomization of the 180th subject in the Company’s Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with prurigo nodularis, the Company had enrolled 50% of the planned subjects in the expanded trial following the July 2020 sample size re-estimation.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 21, 2020

TREVI THERAPEUTICS, INC.

By: /s/ Jennifer L. Good

Name: Jennifer L. Good

Title: President and Chief Executive Officer